Eli Lilly (NYSE:LLY) announced today that it plans to execute price reductions of 70% for its most commonly prescribed insulins.
Indianapolis-based Lilly also plans to expand its Insulin Value Program. This caps patient out-of-pocket costs at $35 or less per month.
The company said it took these actions to “help Americans” in a “complex healthcare system” that can keep them from receiving affordable insulin.
Get the full story at our sister site, Drug Delivery Business News.
Eli Lilly and Company (NYSE:LLY) has elected Mary Lynne Hedley as a new board member, starting May 15, 2022.
Hedley will serve on the board committees related to science and technology, and ethics and compliance.
Hedley is an immunologist and cancer cell biologist with substantial experience in the pharma industry.
Mary Lynne Hedley
Hedley has worked as a senior scientific fellow at the Broad Institute of MIT and Harvard and has served as director, president and chief operating officer of Tesaro, an oncology-focused biotech company she co-founded in 2010. Tesaro commercialized Zejula (niraparib), a PARP inhibitor used for ovarian cancer, fallopian tube and primary peritoneal cancer. GSK acquired Tesaro in 2019 for more than $5 billion.
In 2017, Hedley was awarded an EY Entrepreneurs of the Year Overall National Award.
Hedley has also held senior roles at the biotech Abraxis BioSci…